<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103397</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R 171/2021</org_study_id>
    <nct_id>NCT05103397</nct_id>
  </id_info>
  <brief_title>High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease</brief_title>
  <official_title>High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of low dose methylprednisolone versus high dose on inflammatory&#xD;
      mediators' level and cardioprotective effect after CPB in correction of congenital acyanotic&#xD;
      heart disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized controlled trial, at Ain Shams University hospitals,&#xD;
      Cardiovascular surgery hospital (cardiac surgery unit), Cairo, Egypt.&#xD;
&#xD;
      All patients' legal guardians will sign written informed consent before inclusion.&#xD;
&#xD;
      Randomization will be performed using a computer-generated randomization sequence.&#xD;
&#xD;
      Complete blood count, coagulation tests will be performed for all patients prior to the&#xD;
      planned procedure. For all patients included in this study preoperative evaluation including&#xD;
      a complete airway evaluation (mouth opening, mallampatii grading, thyromental distance, and&#xD;
      evaluation of dentition) will be performed. Standard fasting guidelines will be checked.&#xD;
      (Barash PG et al., 2006).&#xD;
&#xD;
      On patient's arrival to operating room, either inhalational induction by sevoflurane 4-6 %&#xD;
      followed by an intravenous (IV) line insertion or IV induction by Ketamine 1-2 mg /kg and&#xD;
      0.01 mg / kg Atropine. Standard monitoring including electrocardiography (ECG), pulse&#xD;
      oximetry (SpO2). Anesthesia technique: fentanyl 1-5 microgram/kg, will be given during mask&#xD;
      preoxygenation with 100% oxygen, followed by non-depolarizing muscle relaxant (atracurium 0.5&#xD;
      mg /Kg) and then endotracheal intubation and capnography will be applied (Barash PG et al.,&#xD;
      2006).&#xD;
&#xD;
      Femoral artery cannulation by 20 G Leader catheter cannula for invasive blood pressure&#xD;
      (BP)measurement, triple lumen central line will be inserted in internal jugular vein (BRAUN)&#xD;
      by ultrasound guided technique.&#xD;
&#xD;
      After achievement of anesthesia and full muscle relaxation and intubation of the airway, a&#xD;
      blood sample ( 2 ml) will be taken to measure (IL6), Troponin I and blood glucose level. Skin&#xD;
      incision will take place followed by median sternotomy. Heparin 300-500 IU/kg will be given&#xD;
      before aortic cannulation to achieve ACT of 450-480 before starting CPB. Patients will then&#xD;
      be divided into 3 groups:&#xD;
&#xD;
      Group (A) (25 patients) patients will receive 10 mg/Kg methyl prednisolone after induction&#xD;
      before separation to (CPB). (Schroeder et al.,2003).&#xD;
&#xD;
      Group (B) (25 patients) patients will receive 30 mg/Kg methyl prednisolone after induction&#xD;
      before separation to (CPB). (Keski-Nisula et al., 2013).&#xD;
&#xD;
      Group (C) (control group)(25 patients) patients will receive placebo in form of normal&#xD;
      saline.&#xD;
&#xD;
      We will study the different doses of methylprednisolone as there is no standard dose&#xD;
      confirmed in pediatric cardiac surgery. We will compare the low dose with high dose of this&#xD;
      drug to decrease the different side effects of steroids, and we will detect the efficacy by&#xD;
      measuring the inflammatory markers. In our institute the IL 6 is the only available marker to&#xD;
      be measured.&#xD;
&#xD;
      The attending doctor will not give the drug, as another doctor not attending the surgery will&#xD;
      give it. Both the attending doctor and intensivist will be blinded to the drug given.&#xD;
&#xD;
      After surgical correction of cardiac lesion and separation of cardiopulmonary bypass machine,&#xD;
      support of the heart will be achieved and maintained by millirone 0.3-0.7 ug/Kg/min together&#xD;
      with noradrenaline0.01-1 ug/Kg/min. Reversal of heparin by protamine sulphate 1:1 correction.&#xD;
      Vital data, blood pressure and heart rate will be recorded every 10 minutes, the need or the&#xD;
      dose of vasopressors needed will be recorded. After hemostasis and chest closure, patients&#xD;
      will be transferred to ICU (Barash PG et al., 2006).&#xD;
&#xD;
      After admission to ICU, stabilization of patient, another blood sample of (2 ml) to measure&#xD;
      (IL6) , troponin and random blood sugar will be taken, and a third sample will be withdrawn&#xD;
      after 24 hours. Vital data will be recorded every 30 minutes till extubation. Time of&#xD;
      extubation will be recorded. Complications like neurological events, occurrence of new&#xD;
      arrhythmia, wound infection, ICU stay and mortality in the first seven days postoperative&#xD;
      will also be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of Level of IL 6 after CPB time</measure>
    <time_frame>3 months</time_frame>
    <description>comparing level of IL6 in different groups after CPB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Less postoperative complications related to high doses of steroid represented as blood glucose level.</measure>
    <time_frame>3 months</time_frame>
    <description>comparing Less postoperativecomplications related to high doses of steroid represented as blood glucose level.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>low dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low dose group. Group (A) (25 patients) patients will receive 10 mg/Kg methyl prednisolone after induction before separation to (CPB).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose group. Group (B) (25 patients) patients will receive 30 mg/Kg methyl prednisolone after induction before separation to (CPB).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo group. Group (C) (control group)(25 patients) patients will receive placebo in form of normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methyl prednisolone</intervention_name>
    <description>Low dose group .Group (A) 10 mg/Kg methyl prednisolone will be received after induction and before separation to (CPB).</description>
    <arm_group_label>low dose group</arm_group_label>
    <other_name>steroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl Prednisolonate</intervention_name>
    <description>High dose group.Group (B) 30 mg/Kg will be received after induction and before separation (CPB)</description>
    <arm_group_label>high dose group</arm_group_label>
    <other_name>steroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo group.Group (C) (25 patients) patients will receive placebo in form of normal saline</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  We will include pediatric patients ( 1- 16) years old undergoing surgical correction&#xD;
             for congenital acyanotic cardiac lesions needing cardiopulmonary bypass machine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Cyanotic heart disease. 2) Closed cardiac surgeries. 3) Previous cardiac surgery.&#xD;
             4) Patients suffering neurological illness. 5) Diabetics. 6) Emergency procedures. 7)&#xD;
             Patients on preoperative steroid therapy. 8) Adult patients with congenital heart&#xD;
             disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samar mohammed</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>maha Sadek elDerh, Lecturer</last_name>
      <phone>0224190092</phone>
      <email>mahasadek81@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Samar Mohammed, Lecturer</last_name>
      <phone>01006236494</phone>
      <phone_ext>elDerh</phone_ext>
      <email>mahasadek81@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>maha S elDerh, lecturer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>maha sadek El Derh</investigator_full_name>
    <investigator_title>lecturer of anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

